journal article·2026-07Open access

O‐GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer

Jinpeng Wu, Xueting Ren, Zhen Zhai, Lu Wang, Liang Liang, Zengqi Tan, Jiazhen Zhao, Yuxuan Han, Yuhan Li, Feng Guan, Xiang Li

Advanced Science· Volume 13· Issue 37

Abstract

ABSTRACT Major histocompatibility complex class I (MHC‐I) proteins play a crucial role in immune surveillance by presenting newly synthesized antigens to CD8 + T cells on the cell surface. The downregulation of MHC‐I impairs antigen presentation and facilitates immune evasion in bladder cancer. O‐GlcNAcylation, an O‐linked N‐acetylglucosamine modification that is upregulated in various cancers, is increasingly recognized for its role in immune regulation. However, its specific role in antigen presentation remains unclear. In this study, we identified an inverse correlation between O‐GlcNAcylation levels and immune cell infiltration, specifically reducing CD8 + T cell numbers in bladder cancer. Reducing cellular O‐GlcNAcylation significantly enhanced antigen presentation efficiency. We demonstrated that O‐GlcNAcylation of antigen peptide transporter 1 (TAP1), a key transporter in the antigen presentation pathway, disrupts its interaction with MHC‐I, thereby promoting the autophagic‐lysosomal degradation of MHC‐I and impairing CD8 + T cell‐mediated cytotoxicity. Inhibiting O‐GlcNAcylation of TAP1 significantly augmented antitumor immune responses. Collectively, these findings reveal a novel mechanism by which O‐GlcNAcylation facilitates immune evasion in bladder cancer and suggest a potential therapeutic strategy for enhancing TAP/MHC‐I‐mediated antigen presentation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Glycosylation and Glycoproteins Research · Immune Cell Function and Interaction · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Resource Biology and Biotechnology in Western China Provincial Key Laboratory of Biotechnology College of Life Sciences Ministry of Education Northwest University Xi'an Shaanxi China

The Comprehensive Breast Care Center The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi China

Department of Urology The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi China

Shaanxi Province Key Laboratory of Molecular Cardiology School of Medicine Northwest University Xi'an Shaanxi China

Institute of Molecular and Translational Medicine (IMTM) and Department of Biochemistry and Molecular Biology Xi'an Jiaotong University Health Science Center Xi'an Shaanxi China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Shaanxi Province

References (36)

Show source-provided references
1. 10.1038/s41418‐024‐01434‐y10.1038/s41418‐024‐01434‐y ↗
2. 10.1172/JCI17116410.1172/JCI171164 ↗
3. 10.1002/mco2.45510.1002/mco2.455 ↗
4. 10.1038/s41586‐022‐05496‐110.1038/s41586‐022‐05496‐1 ↗
5. 10.1158/2326‐6066.CIR‐18‐075810.1158/2326‐6066.CIR‐18‐0758 ↗
6. 10.1016/j.ccell.2022.09.00710.1016/j.ccell.2022.09.007 ↗
7. 10.1016/j.ccell.2024.02.01310.1016/j.ccell.2024.02.013 ↗
8. 10.1002/advs.20230592210.1002/advs.202305922 ↗
9. 10.1186/s12943‐023‐01899‐410.1186/s12943‐023‐01899‐4 ↗
10. 10.1038/s41388‐019‐1045‐610.1038/s41388‐019‐1045‐6 ↗
11. 10.1186/s12929‐020‐00648‐910.1186/s12929‐020‐00648‐9 ↗
12. 10.3389/fimmu.2024.147404210.3389/fimmu.2024.1474042 ↗
13. 10.1016/j.mam.2020.10088510.1016/j.mam.2020.100885 ↗
14. 10.1073/pnas.221679612010.1073/pnas.2216796120 ↗
15. Genetic Manipulation of OGT Enhances NK Cell‐mediated Cytotoxicity in Tumor Immunity
16. 10.1007/s10456‐024‐09947‐310.1007/s10456‐024‐09947‐3 ↗
17. 10.1038/s41586‐020‐2229‐510.1038/s41586‐020‐2229‐5 ↗
18. 10.1126/science.aan629810.1126/science.aan6298 ↗
19. 10.1038/s41586‐024‐07754‐w10.1038/s41586‐024‐07754‐w ↗
20. 10.1073/pnas.210745311910.1073/pnas.2107453119 ↗
21. 10.1016/j.jare.2019.11.00310.1016/j.jare.2019.11.003 ↗
22. 10.1158/2159‐8290.CD‐20‐081210.1158/2159‐8290.CD‐20‐0812 ↗
23. 10.1016/j.semcancer.2019.03.00210.1016/j.semcancer.2019.03.002 ↗
24. 10.1016/j.mcpro.2022.10022810.1016/j.mcpro.2022.100228 ↗
25. 10.1039/C8CC08416E10.1039/C8CC08416E ↗
26. 10.1186/s13045‐024‐01618‐610.1186/s13045‐024‐01618‐6 ↗
27. 10.1186/s40164‐025‐00693‐w10.1186/s40164‐025‐00693‐w ↗
28. 10.1158/2326‐6066.CIR‐24‐012710.1158/2326‐6066.CIR‐24‐0127 ↗
29. 10.1038/s41467‐022‐34346‐x10.1038/s41467‐022‐34346‐x ↗
30. 10.1111/jpi.1276510.1111/jpi.12765 ↗
31. 10.1038/s41419‐023‐05937‐310.1038/s41419‐023‐05937‐3 ↗
32. 10.1016/j.xcrm.2024.10146510.1016/j.xcrm.2024.101465 ↗
33. Targeting Peptide Antigens Using a Multiallelic MHC I‐Binding System
34. 10.1172/JCI18365610.1172/JCI183656 ↗
35. 10.3389/fimmu.2022.81801510.3389/fimmu.2022.818015 ↗
36. 10.1038/s41419‐024‐07327‐910.1038/s41419‐024‐07327‐9 ↗